robusT®Core Technology Platform
Miracle Biotech's self-developed platform, featuring four patented technologies, overcomes the current challenges in the CAR-T market, and creates a new generation of safe, effective, and off-the-shelf UCAR-T cell therapy products.
Bi-CAR
Dual-position CAR design
To enhance the effect on tumor cells
Identification and killing
To enhance the effect on tumor cells
Identification and killing
Editing
Knockout TRAC, β2M and
HLA-DR genes are used to reduce
GVHD and HVGR risk
HLA-DR genes are used to reduce
GVHD and HVGR risk
Escape
CAR-T cells are upregulated to reduce the attack of the body's innate immune system
eSpan
Strengthen the survival
signals within improve the survival time of CAR-T cells in patients
signals within improve the survival time of CAR-T cells in patients
UCAR-T Innovative Products
Miracle Biotech leverages its proprietary robusT® platform with four core technologies (Editing, Bi-CAR, Escape, eSpan) to break through industry barriers and develop a diverse product pipeline, covering autoimmune diseases, hematological malignancies, and solid tumors. Its safety and efficacy are industry-leading, filling the domestic gap in universal CAR-T cell therapy for solid tumors.
R&D Pipeline
Miracle Bio's UCAR-T cell therapy has successfully developed the CHT101 program, with treatment indications spanning autoimmune diseases, hematologic malignancies, and solid tumors.
Additionally, three dual-target universal CAR-T programs are currently under development, with plans for simultaneous regulatory filings in China and the United States.
Nanjing, China ▪
9 Weidi Road, Qixia District
B5, Jiangsu Life Science and Technology Innovation Park
159 5057 4195/138 0159 0731
service@njmiracle.com
Follow Us